Tratamiento oncológico activo de la enfermedad neoplásica avanzada y terminal

Medicina Clinica

Volumn 114, Issue 8, 2000, Pages 302-307

  Sanz Ortiz, Jaime ^a   Rivera Herrero, Fernando ^a   De Juan Ferré, Ana ^a   Vega Villegas, Ma Eugenia ^a  

^a HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CAMPTOTHECIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; FLUOROURACIL; GEMCITABINE; IRINOTECAN; NAVELBINE; PACLITAXEL; VINDESINE;

ADVANCED CANCER; CANCER CHEMOTHERAPY; REVIEW; TERMINAL DISEASE; TREATMENT PLANNING; CANCER STAGING; HUMAN; NEOPLASM; PATHOLOGY; TERMINAL CARE;

HUMANS; NEOPLASM STAGING; NEOPLASMS; TERMINAL CARE;

EID: 0034603269     PISSN: 00257753     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0025-7753(00)71276-0     Document Type: Article

References (43)

1. Skrabanek P. La ideología de la salud. En: Skrabanek P, editor. La muerte de la medicina con rostra humano. Madrid: Diaz de Santos S.A., 1999; 1-35.
2. Sikora K, Advani S, Koroltchouk V, Magrath I, Levy L, Pinedo H et al. Fármacos esenciales en el tratamiento del cáncer: ¿es viable la identificación de los fármacos citotóxicos esenciales? Ann Oncol (ed. esp.) 1999; 8: 604-609.
3. Alonso I, Regidor E, Rodríguez C, Gutiérrez-Fisac JL. Principales causas de muerte en España, 1992. Med Clin (Barc) 1996; 107: 441-445.
4. Ihde DC. Chemotherapy of lung cancer. N Engl J Med 1992; 327: 1434-1441.
5. Stanely KE. Prognostic factors for survival in patients with inoperable lung cancer. J Natl Cancer Inst 1980; 65: 25-32.
6. Rapp E, Pater JL, Willan A, Cornier Y, Murray N, Evans WK et al. Chemotherapy can prolong survival in patients with advanced non-small-cell-cancer: report of a Canadian multicenter randomized trial. J Clin Oncol 1988; 6: 633-641.
7. Carteri G, Cartel F, Cantone A, Causarano D, Genco G, Tobaldin A et al. Cisplatin-cyclosphosphamide-mitomycin combination chemotherapy with sopportive care versus supportive care alone for treatment of metastatic non-small-cell-cancer. J Natl Cancer Inst 1993; 85: 794-800.
8. Ganz PA, Figlin RA, Haskell CM, La-Soto N, Siau J. Supportive care versus supportive care and combination chemotherapy in metastatic non-small-cell lung cancer: does chemotherapy make a difference? Cancer 1989; 63: 1271-1278.
9. Woods R, Williams C, Levi J, Page J, Bell D, Byrne M et al. A randomized trial of cisplatin and vindesine versus supportive care only in advanced non-small-cell lung cancer. Br J Cancer 1990; 61: 608-611.
10. Cellerino R, Tummarello D, Guidi F, Isidori P, Raspugli M, Biscottini B et al. A randomized trial of alternaring chemotherapy for patients versus best supportive care in advanced non-small-cell lung cancer. J Clin Oncol 1991; 9: 1453-1461.
11. Ellis PA, Smith IE, Hardy JR, Nicolson MC, Talbot DC, Ashley SE et al. Symptom relief with MVP (mitomicine C, vinblastine and cisplatin) hemotherapy in advanced non-small cell lung cancer. Br J Cancer 1995; 71: 366-370.
12. Fernandez C, Rossell R, Abad-Esteve A, Monras P, Sericho IM, Roviralta M. Quality of life during chemotherapy in non-small cell lung cancer patients. Acta Oncol 1989; 28: 129-133.
13. Kris MG. What does chemotherapy have to offer with advanced-stage non-small cell lung cancer? Semin Oncol 1998; 25 (Supl 8): 1-4.
14. ASCO Special article. Clinical Practice Guidelines for the treatment of unresectable non small cell lung cancer. J Clin Oncol 1997; 15: 2996-3018.
15. Sandler A, Ettinguer DS. Gemcitabine: single-agent and combination therapy in non-small cell lung cancer. The Oncologist 1999; 4: 241-251.
16. Anderson H, Betticher DC, Ranson M. Symptomatic benefit from gemcitabine and other chemotherapy in advanced non-small cell lung cancer: changes in performance status and tumor-related symtoms. Anticancer Drugs 1995; 6 (Supl 6): 39-48.
17. Thongpraset S, Sanguanmitra P, Juthapan W, Clinch J. Relationship between quality of life and clinical outcomes in advanced non-small cell lung cancer: best supportive care (BSC) versus BSC plus chemotherapy. Lung Cance 1999; 24: 17-24.
18. The Elderly Lung Cancer Vinorebine Italian Study Group. Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small lung cancer. J Natl Cancer Inst 1999; 91: 66-72.
19. Cardenal J, López-Cabrerizo MP, Antón A, Alberola V, Massuti B, Carrato A et al. Randomized phase III study of gemcitabine-cisplatin versus etoposide-cisplatin in treatment of locally advanced or metastatic non-small-cell lung cancer. J Clin Orcol 1999, 17: 12-18.
20. Thatcher N, Ramson M, Lee SM, Niven R, Anderson H. Chemotherapy in non-small cell lung cancer. Ann Oncol 1995; 6 (Sup): 82-95.
21. Souquet PJ, Chauvin F, Boissel JP, Cellerino R, Cormier Y, Ganz PA et al. Polychemotherapy in advanced non small cell lung cancer: a meta analysis. Lancet 1993; 342: 19-21.
22. Non-Small Cell Lung Caner Collaborative Group. Chemotherapy in non small cell lung cancer: a meta analysis using updated data on individual patients from 52 randomised clinical trials. Br Med J 1995; 311: 899-909.
23. Marino P, Pampallona S, Preatoni A, Cantoni A. Invernizzi F. Chemotherapy vs supportive care in advanced non small cell cancer: results of a meta analysis of the literature. Chest 1994; 106: 861-865.
24. Grile R, Osman AD, Julian JA. Chemotherapy for advanced non small cell lung cancer: how much benefit enough? J Clin Oncol 1993; 11: 1866-1872.
25. Fills PA, Smith IE, Hardy JR, Nicolson MC, Talbot DC, Ashley SE et al. Symptom relief with MVP (mitomycin C, vinblastine and cisplatin) chemotherapy in advanced non-small cell lung cancer. Br J Cancer 1995; 72: 356-370.
26. Fernández C, Rosell R, Abad-Esteve A. Quality of life during chemotherapy in non small cell lung caner patients. Acta Oncol 1989; 28: 129-133.
27. Hardy JR, Noble T, Smith IE. Symptom relief with moderate dose chemotherapy (mitomycin-C, vinblastine, and cisplatin) in advanced non-small cell lung cancer. Br J Cancer 1989; 60: 764-766.
28. Jaakkimainen L, Goodwin PJ, Pater J. Couting the cost of chemotherapy in a National Cancer Institute of Canada randomized trial in non-small cell lung cancer. J Clin Oncol 1990; 8: 1301-1309.
29. Raby B, Pater J, Mackillop W. Does knowledge guide practice? Another look at the management of non-small cell lung career J Clin Oncol 1995; 13: 1904-1911.
30. The Nordic Gastrointestinal Tumour Adjuvant Therapy Group. Expectancy or primary cnemotherapy in patients with advanced asymptomatic colorectal cancer: a randomised trial. J Clin Oncol 1992; 10: 896-903.
31. Scheithauer W, Rosen J, Kornek GV, Sebesta C, Depisch D. Randomised comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer. Br Med J 1993; 306: 752-755.
32. Huyssens-Stiftung EV, Knapsschaft GMBH. Comparing irinotecan with best suppostive care and infusional 5-fluorouracil: a critical evaluation of the resuts of two randomized phase III trials. Semin Oricol 1999; 26 (Supl 5): 21-23.
33. Cunningham D, Glimelius B. A phase III study of irinotecan (CPT-11) versus best supportive care in patients with metastatic colorectal cancer who have failed 5-fluorouracilo therapy. Semin Oncol 1999; 26 (Supl 5): 6-12.
34. Burris HA III, Moore MJ, Andersens, Green MR, Rothenberg ML, Modiano MR. Improvements in sufvival and clinical benefit with gemcitabine as first-line therapy for patients with advanced J Clin Oncol 1997; 15: 2403-2413.
35. Glimeilus B, Hoffman K, Sjodén P-O, Jacobsson G, Sellstrom H, Enander L-K et al. Chemotherapy improves surviva and quality of life in advanced pancreatic and biliary cancer. Ann Oncol 1996; 7: 593-600.
36. Kurman MR. Systemic therapy (chemotherapy) in the palliative treatment of cancer pain. En: Part RB, editor. Cancer pain Filadelfia: JB Lippincott Co., 1993; 251-274.
37. Sanz-Ortiz J, Gómez-Batiste X, Gómez Sancho M, Nun̄ez Olarte JM. Guia de cuidados pa lativos. Recomendaciones de la Sociedad Española de cuidados paliativos (SECPAL). Madrid; Ministerio de Sanidad y Consumo, 1993.
38. Ebell MH. Prearrest predictors of survival following in-hospital cardiopumonary resucitation: a meta-analysis. J Fam Pract 1992; 34: 551-558.
39. Ebell MH. Practical guidelines for do-not resuscitate orders. Am Fam Physician 1994; 50: 1293-1299.
40. Stewart K, Bacon M, Bowker L. Patients with intreatable cancer almost never survive cardiopulmonary resuscitation. Br Med J 1998; 316: 1166-1167.
41. Hendrick JM, Pijls NH. Cardiopulmonary resuscitation in cases of malignant disease. Lancet 1998; 2: 1501.
42. Meystre CJN, Burley NMJ, Ahmedzai S. What investigations and procedures do patients in hospices want? Interview-based survey of patients and their nurses. Br Med J 1997; 315: 1202-1203.
43. Sanz Ortiz J. Tecnologia y beneficencia del enfermo. Med Clin (Barc) 1999; 112: 380-383.